MSN TOFACITINIB (Accelagen Pty Ltd)

Rheumatoid Arthritis (RA)

TRADE NAME is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to methotrexate. MSN Tofacitinib can be used alone or in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs), including methotrexate.

Psoriatic Arthritis (PsA)

TRADE NAME in combination with conventional synthetic DMARDs is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response to a prior DMARD therapy.

Ulcerative Colitis (UC)

TRADE NAME is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.

Ankylosing Spondylitis (AS)

TRADE NAME is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.

Juvenile Idiopathic Arthritis (JIA)

TRADE NAME is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis, extended oligoarthritis and systemic juvenile arthritis without systemic features for six months) and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs.